alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 651–675 of 863 studies · tagged Prevention (page 27 of 35) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Pretreatment with metformin prevents microcystin-LR-induced tau hyperphosphorylation via mTOR-dependent PP2A and GSK-3β activation

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Environmental toxicology 2021-08-25

Microcystin-leucine-arginine (MC-LR) is a toxin secreted by freshwater cyanobacteria that is considered a potential environmental risk factor for Alzheimer's disease (AD). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Avoiding Over-Reliance on Multi-Domain Interventions for Dementia Prevention

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of Alzheimer's disease : JAD 2022

Given the unknown therapeutic value of targeting Alzheimer's disease pathology and the discovery of robust risk factors for dementia, non-pharmacological risk reduction (RR) is increasingly offered as an alternative to targeting Alzheimer's disease pathology. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

From Dementia to Eumentia: A New Approach to Dementia Prevention

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Neuroepidemiology 2022-05-25

Since environmental, socioeconomic, and individual risk factors contribute to dementia, we proposed a Comprehensive, Customized, Cost-effective APProach (the CCC-APP) implemented in actionable units with the focus on promoting brain health (eumentia). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

[Alzheimer's disease. Current evidence on the preventive role of nutrition]

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Nutricion hospitalaria 2023-11-22

several dietary components have been positively associated with AD prevention, including intake of complex carbohydrates, fiber, omega-3, plant-based proteins, vitamins (folates, choline, vitamin D, C, B6 and B9), zinc, some bioactive compounds such as flavonols and probiotics. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Neurotrophic Treatment Initiated During Early Postnatal Development Prevents the Alzheimer-Like Behavior and Synaptic Dysfunction

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of Alzheimer's disease : JAD 2021

P021 treatment during early development prevented cognitive impairment and increased expressions of pCREB and BDNF that activated downstream various signaling cascades such as PLC/PKC, MEK/ERK and PI3K/Akt, and ameliorated synaptic protein deficit in 4-month-old 3xTg-AD mice. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Lifestyle interventions for dementia risk reduction: A review on the role of physical activity and diet in Western and Asian Countries

✓ Peer-reviewed alzhub usefulness score 40 out of 100. The Journal of Prevention of Alzheimer s Disease 2025-01-23

Dementia, is a critical global public health challenge with no effective pharmacological treatments. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Intrinsic factors associated with engagement in healthy lifestyle behaviors for dementia risk reduction in midlife

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Alzheimer s & Dementia Behavior & Socioeconomics of Aging 2025-04-06

LPA identified four intrinsic profiles: Profile 1 had low motivation; Profile 2 had high motivation and self-efficacy, but poor dementia knowledge; Profile 3 had moderate motivation; and Profile 4 had low motivation and high apathy. 5 key findings →

Participants: 347 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Integrative Strategies for Preventing and Managing Metabolic Syndrome: The Impact of Exercise and Diet on Oxidative Stress Reduction—A Review

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Life 2025-05-08

Metabolic syndrome (MetS) is characterized by central obesity, insulin resistance, hypertension, dyslipidemia, and chronic inflammation, significantly increasing the risk of cardiovascular disease and type 2 diabetes. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Lessons from the Implementation of the Sendai Framework for Disaster Risk Reduction from Latin America and the Caribbean

✓ Peer-reviewed alzhub usefulness score 40 out of 100. International Journal of Disaster Risk Science 2025-01-21

Over the past decade, Latin America and the Caribbean (LAC) have made progress in implementing the Sendai Framework for Disaster Risk Reduction 2015–2030 (SFDRR). 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Multidomain interventions for prevention of dementia: Achievements, challenges and future perspectives

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Geriatrics and gerontology international/Geriatrics & gerontology international 2025-06-17

With the aging of the population, the number of persons with dementia is expected to increase worldwide, making the establishment of preventive strategies for dementia an urgent issue. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Modifiable Lifestyle Risk Factors and Strategies for Slowing the Progression of Age-Related Macular Degeneration

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Vision 2025-02-23

Age-related macular degeneration (AMD) is a multifactorial disorder influenced by genetic, lifestyle, nutritional, and systemic health factors that contribute to increased oxidative stress and chronic inflammation in the retina. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Advancing dementia care: a review of Italy’s public health response within the WHO Global Action Plan and European strategies

✓ Peer-reviewed alzhub usefulness score 40 out of 100. BMJ Public Health 2025-07-01

IFAD activities led to substantial progress in dementia care services, with memory clinics, residential care facilities and daycare centres mapped, revealing regional disparities in service provision. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Preserved cognitive–functional phenotype in centenarians and its association with modifiable risk factors for dementia: Results from the Colombian centenarians project

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Alzheimer s & Dementia 2025-12-01

Among 160 centenarians, 63.7% did not meet the PCFP criteria and were classified as having dementia. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

From across this tag

10 of the 859 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed